Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07366489

Efficacy and Safety of the RDI Mode in Endoscopic Submucosal Dissection

Conventional white-light endoscopy (WLE) is hampered by insufficient contrast when attempting to identify deep vessels and active bleeding sites; visibility drops further when blood pools or spurts obscure the field, resulting in significantly lower hemostatic efficiency. Red dichromatic imaging (RDI), a novel image-enhanced endoscopic modality, has recently been shown to improve the visualization of deep-lying vessels and bleeding points, shorten hemostasis time and potentially increase overall procedural efficiency.

Although retrospective series have suggested that RDI may facilitate intra-operative bleeding control and better delineation of the submucosal plane during endoscopic submucosal dissection (ESD), high-level evidence from multicenter, randomized, controlled trials (RCTs) is lacking. No study has yet demonstrated superiority over WLE with respect to critical endpoints such as en-bloc resection rate, procedure time, complication rate and operator mental workload.

The investigators therefore designed a multicenter RCT to systematically compare the efficacy and safety of full-procedural RDI with conventional WLE during ESD.

The primary outcome parameter is the mean resection speed (mm²/min) achieved with RDI versus conventional white-light endoscopy during ESD.

The secondary outcome parameters are: complete resection (R0) rate, en-bloc resection rate, resection margin, number of intra-procedural bleeding episodes, intra-procedural blood loss, intra-procedural hemostasis time, other intra-procedural adverse events, and post-procedural adverse events.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Early gastric cancer or precancerous lesions, early esophageal cancer or precancerous lesions, or early colorectal cancer/polyps that meet ESD indications.
  • ESD procedure to be performed at a participating center.
  • Lesion diameter 20-60 mm. ⑤ Written informed consent provided voluntarily.

Exclusion criteria

① Foreigners.

② Severe coagulopathy (platelet count <50×10⁹/L or INR >1.5), significant cardiopulmonary disease, or any other contraindication to endoscopic therapy.

③ Imaging evidence of distant metastasis or lymph-node metastasis.

Treatment and study plan

RDI

Other

Throughout the entire ESD dissection, the RDI mode is used continuously for submucosal dissection (while white-light endoscopy may be employed for observation and marking).

Primary outcomes

  1. mean resection speed (mm²/min) achieved with RDI versus conventional WLE during ESD

    Time frame: Periprocedural

    The resection speed is calculated as the area on the specimen-fixation board divided by the time elapsed from the first mucosal incision to complete dissection of the lesion.

Secondary outcomes

  1. complete resection (R0) rate

    Time frame: Periprocedural

    complete resection (R0) rate

  2. en-bloc resection rate

    Time frame: Periprocedural

    en-bloc resection rate

  3. resection margin

    Time frame: Periprocedural

    vertical and horizontal resection margin

  4. number of intra-procedural bleeding episodes

    Time frame: Periprocedural

    number of intra-procedural bleeding episodes

  5. intra-procedural blood loss

    Time frame: Periprocedural

    intra-procedural blood loss

  6. intra-procedural hemostasis time

    Time frame: Periprocedural

    intra-procedural hemostasis time

  7. other intra-procedural adverse events

    Time frame: Periprocedural

    perforation, infection, and other adverse eventes

  8. post-procedural adverse events

    Time frame: From enrollment to 30 days after the procedure.

    perforation, infection, delayed gastrointestinal bleeding, and other adverse events,

Study contacts

Contact information is provided by the study sponsor or research team.

Jia C Sun, MM

CONTACT

[email protected]

86-20-38379764

Sponsors and collaborators

Lead sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Other

Collaborators

  • Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Guangdong Second Provincial General Hospital

Registry information

Official study title

Efficacy and Safety of the RDI Mode in Endoscopic Submucosal Dissection: a Multicenter, Randomized Controlled Study

Acronym: RM-ESD

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 26, 2026
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.